ABSTRACT
Background Multidrug-resistant Pseudomonas aeruginosa (MDRPA) poses significant challenges in hospital settings. Understanding the effects of the unprecedented changes brought by the COVID-19 pandemic on antimicrobial resistance in P. aeruginosa (PA) is essential to inform stewardship efforts. This study investigated the dynamics of antimicrobial resistance in PA bacteremia after the start of the pandemic.
Methods This single-centre retrospective cohort study included adult inpatients with PA bacteraemia at the University Hospital Zurich between January 2014 and December 2023. Data were retrieved from electronic records. The primary outcome was the association between the start of the COVID-19 pandemic and PA with MDR, defined as resistance to ≥3 of 5 antibiotic classes. We used logistic regression to adjust for age, sex and ICU treatment, accounting for multiple bacteremia instances within the same patient using cluster-robust standard errors. Secondary outcomes included changes in resistance patterns and patient demographics, with antimicrobial exposure assessed as median monthly days of therapy (DOT).
Results A total of 493 instances of PA bacteremia in 333 patients were observed during the study period. The proportion of MDRPA declined from 21% (62/291) pre-pandemic to 9% (19/202) post-pandemic (adjusted OR 0.38, 95% CI 0.18–0.79, p=0.01). The occurrence of MDRPA during hospitalisation following an initial instance of non-MDRPA bacteremia was rare and unlikely to happen earlier than after two weeks. Antimicrobial consumption patterns shifted after the start of the pandemic, with reduced use of amikacin and ciprofloxacin and increased use of cefepime and meropenem. Overall inhospital-mortality among patients with MDRPA bacteraemia remained high (28%), with no substantial differences before and after the pandemic (adjusted hazard ratio 1.57, 95% CI 0.43–5.67, p=0.49).
Conclusion We observed a decline in MDRPA occurrence after the start of the COVID-19 pandemic, possibly driven by intensified infection control measures, shifts in antimicrobial use, and changes in patient populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Swiss National Science Foundation Starting Grant 211422 to SDB, University of Zurich CRPP Precision medicine for bacterial infections to SDB, USZ Foundation USZF270808 to SDB and Beatrice Ederer-Weber Foundation to SDB. The funders had no role in study design, performance, analysis and interpretation of findings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Canton Zurich reviewed the study protocol (Kantonale Ethikkommission Zurich BASEC ID Req-2022-00076) and concluded that the study did not meet the criteria for requiring ethical approval within its remit. All research was carried out in accordance with Good Clinical Practice (GCP) standards. The data required for this study were anonymized before their use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
ABBREVIATIONS
- MDRPA
- Multidrug-Resistant Pseudomonas aeruginosa
- PA
- Pseudomonas aeruginosa
- WHO
- World Health Organization
- CDC
- Centers for Disease Control and Prevention
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- ICU
- Intensive Care Unit
- HR
- Hazard Ratio
- CI
- Confidence Interval
- OR
- Odds Ratio
- IQR
- Interquartile Range
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.